SCLX Stock — Scilex Holding Company: Cash, EV, Pipeline

Share price

$5.15

Market cap

$43.7M

Cash

$0.6M

Enterprise value

$123.9M

Balance sheet

Cash	$0.6M
Debt	$80.8M
Net cash	-$80.2M
Enterprise value	$123.9M
Basic shares	7.0M shares
Fully diluted shares	17.0M shares
Fully diluted market cap	$87.8M
Cash per share	$0.08

Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.

Price history

Loading SCLX daily closes…

Loading price history…

Pipeline assets

SP-102

Phase 3 · Active Modality: dexamethasone sodium phosphate viscous gel for epidural injection

Aliases SEMDEXA

Indications

lumbosacral radicular pain (sciatica) (Phase 3)

Status note Second Phase 3 study initiated September 2025; no discontinuation disclosed.

SP-103

Phase 2 · Active Modality: lidocaine topical system

Partnerships RoyaltyVest (ex-U.S. licensee for lidocaine products)

Indications

chronic neck pain (Phase 2)
acute low back pain (Phase 2 completed) (Phase 2)

Status note Phase 2 trial in acute low back pain completed; being developed for chronic neck pain; no discontinuation disclosed.

SP-104

Phase 1 · Active Modality: delayed-release oral capsule (low-dose naltrexone hydrochloride)

Partnerships Aardvark Therapeutics (asset/IP acquisition)

Indications

fibromyalgia (Phase 1)

Status note Phase 1 trials completed; company states it is committed to pursuing clinical development for fibromyalgia; no discontinuation disclosed.

ZTlido

Approved · Active Modality: lidocaine topical system

Partnerships RoyaltyVest (ex-U.S. licensee); Oishi Koseido (product development agreement)

Indications

neuropathic pain associated with postherpetic neuralgia (PHN) (Approved)

Status note FDA-approved prescription lidocaine topical system 1.8%; commercial product.

ELYXYB

Approved · Active Modality: oral solution (celecoxib)

Partnerships BioDelivery Sciences International and Collegium Pharmaceutical (rights acquisition); Dr. Reddy's Laboratories (know-how/patent license obligations assumed)

Indications

acute treatment of migraine with or without aura in adults (Approved)

Status note FDA-approved ready-to-use oral solution; commercial product.

GLOPERBA

Approved · Active Modality: oral solution (colchicine)

Partnerships Romeg (RxOmeg Therapeutics) (license and commercialization agreement)

Indications

prophylaxis of painful gout flares in adults (Approved)

Status note FDA-approved liquid oral colchicine; commercial product.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

No specialist-fund holders in 13F data for this company.

SCLX — Scilex Holding Company

Balance sheet

Price history

Pipeline assets